The Oxford journal Rheumatology published the results of a study conducted to measure how effective the Bioelectronics Company’s Actipatch was in treating chronic osteoarthritis pain in the human knee today. The date says December 24th was the online publishing date. This may have been for subscribers. Bioelectronics announced it today, but the results have been known, mainly, for a while. The significance of this is a reputable, peer reviewed journal published the results in a nice layout with charts and references. This paper was already mainly priced in to the stock.

The study compared two groups, those who used the Actipatch (a device which uses PEMF (pulsed electromagnetic fields) to a placebo using group. They monitored a couple of tests, such as quality of life and increase or decrease of “NSAIDS” (non steroidal anti-inflammatory drugs).

The paper can be found here.

The results were quite stunning, really, though I say this without access to the raw data tables. I like to crunch my own numbers.

Roughly, 20% improvement in pain relief for Patch users, 2 to 3 % improvement for Placebo. The chart below tells the tale.

Fig. 2

Also gauged was the use of NSAIDS in the Actipatch versus Placebo groups. This is important, so this is what I am focusing on, since this is where this study could possibly use some improvement. I pasted Table 3 from the paper at the bottom for illustration.

I read this table as stating at the end of a month, 46% of Patch users were using NSAIDS/analgesics as opposed to 90% of placebo users. So far so good, and the Patch could be approved by the FDA on the strength of this alone.  The FDA has approved on less, statistically.

However, the second part of the table could have been interpreted better in the footnote.

10% of placebo group started using NSAIDS/analgesics, while 0% of Patch users started taking drugs after a month.

However, if you were using drugs and had the Patch, it looks like 26% stopped using, while 23% of placebo users stopped. This is not very statistically significant. I get 23% by subtracting 3 from 10 and dividing by 30. So only 7 of the Placebo users actually stopped taking drugs. This is a statistical tie, and this is the part of the study I think could be fine tuned.

Liver and kidney damage combined with drug addiction is lethal, and there is a real need for a treatment which decreases these, especially in combination.

From the paper:

“Another interesting aspect of the interaction between electromagnetic fields and pain is related to opioid function; it has been demonstrated in mice that the induction of analgesia by electromagnetic exposure was equivalent to a moderate dose of morphine [32]. ”

So, instead of a study which treats drug use in a Boolean way (that is, you are either using pain killer drugs or not), there needs to be a study for tapering off using the Patch versus the placebo. If people use lower doses of drugs, odds of addiction, kidney, and liver damage are decreased. A primary benefit of the Actipatch is it will help people lower the dose. They might still be taking NSAIDS/analgesic drugs, but will just require less of them.

The patients in this study using the Patch and NSAIDS/analgesics (fully prescribed amounts) might have been been able to use a lower dose, but the study does not capture this.

I do not want to seem like a negative Nelly. The study was tremendous. I am simply pointing out that big selling point of the Patch is underexplored here. This is a not a comment on the pending FDA approval, which should occur, rather an observation about the study. Dr. Bagnato talks about further studies going directly against pain drugs with the Patch. “Tapering off” Placebo versus Actipatch, should be a part of this study.

*This blog concerns itself with topics including drug trafficking throughout the world.

How many people have you personally known who have died of terrorism as opposed to people who have overdosed, either dying or sustaining liver, kidney, or addiction problems? The magnitude of the problem is huge, and the Drug War is used as an excuse to take away our civil liberties and perpetrate a flawed foreign policy. Americans are not the only victims of the Drug War. Whether coincidentally or not, USA government policy works in a contradictory fashion. The Taliban had eliminated poppy cultivation in Afghanistan, but the USA and Britain opened that market back up again. A lot of people are dying from heroin addiction, and it is Satanic, not a word I use lightly.

A lot of people get hooked, innocently enough, by our own Medical establishment, which is terminally ignorant, seemingly, of the nature of the addictive personality. The end results is people move from prescribed drugs to street drugs, a self-fueling prophecy.

There used to be a blogger who got shut down who said the Queen of England regarded heroin addicts as annuities. Certainly, every President of the USA has been related to her, including Obama on the American side. The FDA needs to approve alternative remedies to drugs. The Patch has no side effects of note, but drugs are killing people. The benefits of FDA approval for the Actipatch outweigh the minimal risk.

**Check links for free books (periodically).

 

Table 3

Changes in intake of NSAIDs/analgesics

NSAID/analgesic intake PEMF (n = 30) Placebo (n = 30)
Subject’s daily drug intake at 1 months
    NSAIDs, n (%) 6 (20) 12 (40)
    Analgesics, n (%) 8 (26) 15 (50)
Changes in drug intake at 1 month follow-up
    Started NSAIDs/ analgesics, n (%) – (0) 3 (10)
    Stopped NSAIDs/ analgesics, n (%) 8 (26) 10 (33)
  • At the end of the trial, 46% subjects from the PEMF group and 90% patients from the placebo group were under treatment with NSAIDs/analgesics. In the PEMF group, 26% (n = 8) stopped the pharmacological therapy compared with baseline, whereas in the placebo group 10% (n = 3) started a new therapy with NSAIDs/analgesics and one patient stopped previous treatment. PEMF: pulsed electromagnetic fields.

 

Advertisements